The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $126,095.20 firm fixed price purchase order to Agilent Technologies Inc. Customer Service And Sales Division. Under the terms of the contract, Agilent will provide 17 single lot-matched fluorescent DNA probe labeling kits, 100 lot-matched cDNA expression microarrays, gene expression hybridization and wash pack kits, and shipping and handling services in support of the agency's viral pathogenesis and evolution studies. The solicitation specifically sought these Agilent reagents to enable global expression analysis of nasal and blood samples from participants in a Phase II universal influenza vaccine clinical trial being conducted by the National Institute of Allergy and Infectious Diseases Laboratory of Infectious Disease in Bethesda, Maryland. Place of performance is Marshallton, Delaware and the period of performance spans from August 31, 2023 through December 29, 2023.
Generated 12/24/23, 12:55 PM